Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab for Delayed Graft Function in Kidney Transplant
NCT06830798Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of ravulizumab in delayed graft function (DGF), sponsored by Alexion Pharmaceuticals. Started May 2025; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT06830798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830798.